AXGN:NASDAQ
AxoGen, Inc Common Stock
57,34 $
arrow_upward
+0,68%(+0,38) 1D
19 қар., 13:52:47 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
57,43 $
High
58,35 $
Low
56,61 $
Mkt. cap
3,42 млрд
Avg. vol.
1,87 млн
Volume
398,22 м.
52-wk high
59,72 $
52-wk low
25,16 $
EPS
-0,65 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
Open
57,43 $
High
58,35 $
Low
56,61 $
Mkt. cap
3,42 млрд
Avg. vol.
1,87 млн
Volume
398,22 м.
52-wk high
59,72 $
52-wk low
25,16 $
EPS
-0,65 $
Beta
1,21
Shares outstanding
59,73 млн
No. of employees
622
News stories
From web sources and news partners
TradingView
·
2 күн бұрын
AXGN: Breast growth accelerates as prostate launch and margin initiatives approach
Investing.com UK
·
2 күн бұрын
AxoGen at Jefferies conference: growth plan faces margin pressure By Investing.com
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Флорида, Америка Құрама Штаттары
SectorHealth Care
IndustryMedical device
Websiteaxogeninc.com